Mivocabtagene Autoleucel

N/A

Report date: 2026/05/14 15:04:57

Base Information

Drug NameMivocabtagene Autoleucel
Drug Alias Name靶向CD19自体CAR-T疗法(Kyverna Therapeutics）Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy (Kyverna Therapeutics)Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy (Kyverna Therapeutics)Autologous anti-CD19 CAR T cell therapy (Kyverna Therapeutics)Miv-cel +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, DiffuseScleroderma, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[4] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityCharite University, Berlin, GermanyCharité – Universitätsmedizin Berlin +[4] 
Inactive CompaniesN/A
Active IndicationsScleroderma, DiffuseScleroderma, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A